Ascentage Pharma Announces 2026 AGM Poll Results and Clinical Data Presentations at ASCO

Ascentage Pharma Group International filed a Form 6-K reporting the results of its Annual General Meeting (AGM) held on May 20, 2026. Shareholders approved all proposed resolutions, including the re-election of directors Dr. Wang Shaomeng, Dr. Lu Simon Dazhong, and Dr. David Sidransky. Notably, shareholders approved the "Third Amended and Restated Memorandum and Articles of Association" and granted mandates for the board to allot new shares (up to 20%) and repurchase existing shares (up to 10%). Specific approvals were also granted for the issuance of Restricted Share Units (RSUs) and Options to CEO Dr. Yang Dajun and CMO Dr. Zhai Yifan under the company's 2022 RSU and Post-IPO Share Option schemes. Additionally, the filing notes that the company released latest clinical data from multiple trials at the ASCO 2026 conference, which were detailed in separate press releases and announcements dated May 21 and May 22, 2026. The company remains incorporated in the Cayman Islands with its principal executive offices in Suzhou, China.